In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.


The ampicillin/sulbactam combination demonstrates synergy in addressing bacterial strains resistant to ampicillin, thus providing broader coverage. This drug combination incorporates a β-lactamase inhibitor into ampicillin, extending coverage against potentially resistant bacteria. The ampicillin/sulbactam combination has been approved by the U.S. Food and Drug Administration (FDA) for treating skin and skin structure infections, intra-abdominal infections, and gynecological infections. This activity emphasizes the appropriate use of ampicillin/sulbactam by providing information on its indications, mechanism of action, adverse events, and drug interactions, which is crucial for the interprofessional healthcare team to ensure the delivery of optimal patient care.

Publication types

  • Study Guide